Abstract 13150: The Economic Implications of Non adherence to Aspirin in Patients With Prior Primary Cardiovascular Events
Introduction: Adherence to medications for secondary prevention of cardiovascular events has been shown to be poor in both general and high risk populations. Non adherent patients are at higher risk of experiencing another CV event, leading to adverse clinical events and high costs. Few prior studies have explored the economic and consequences of non adherence to aspirin in relation to cardiovascular health. Hypothesis: Improved adherence to aspirin will lead to lower healthcare costs and improved long term survival rates. Methods: We developed a generalizable Markov model to estimate the cost effectiveness of aspirin adherence. The rates of aspirin adherence, events and costs were gathered from published literature. We applied the model separately to a general (low risk) population with no comorbidities and a high risk population with type II diabetes. Outcomes of interest included fatal and nonfatal events, including secondary myocardial infarction (MI) stroke, other clinical CV events including PAD re.